secwatch.observer — SEC 8-K summary
======================================

Issuer:     Dyne Therapeutics, Inc. (DYN)
CIK:        0001818794
Form:       8-K
Filed at:   2024-05-22T23:59:59+00:00
Accession:  0001193125-24-144470
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Dyne Therapeutics prices $325.5M public offering of 10.5M shares at $31.00 per share
--------------------------------------------------------------------------------

- Gross proceeds of $325.5M; net proceeds estimated at $305.4M ($351.4M if underwriters' option is fully exercised).
- Underwriters include Morgan Stanley, Jefferies, Stifel, and Guggenheim Securities; closing expected May 24, 2024.
- Company granted 30-day option for underwriters to purchase an additional 1.575M shares at the same price.
- Net proceeds plus existing cash expected to fund operations at least into the second half of 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1818794/000119312524144470/0001193125-24-144470-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1818794/000119312524144470/d812513d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-144470

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer